Abstract：OBJECTIVE: To study and compare the prophylatic efficacy of levetiracetam, valproate and phenobarbital on febrile convulsions in rats. METHODS: Sixty Wistar rats were randomly administered with levetiracetam (200 mg/kg), valproate (250 mg/kg), phenobarbital (30 mg/kg) or normal saline (8 ml/kg) for 5 days. Five days later, febrile convulsions were induced by hyperthermal bath (45℃). The latency, duration and the severity of seizures were observed. RESULTS: In all the three drug-treated groups, the latency was significantly prolonged, and the duration and the severity of seizures were notably reduced compared with the saline group（P< 0.05 or 0.01）. The phenobarbital group had the shortest duration of seizures and the least severe seizures among the three drug-treated groups. There were no significant differences between the levetiracetam and valproate groups. CONCLUSIONS: Continuous administration of levetiracetam, valproate or phenobarbital is effective in preventing recurrent febrile convulsions in rats. Phenobarbital appears to be more effective than levetiracetam and valproate. There were no significant differences in the prophylactic efficacy between levetiracetam and valproate.［Chin J Contemp Pediatr, 2010, 12 (7):573-575］
CHENG Min,HUANG Zhi,LI Si-Xiu. Prophylactic efficacy of levetiracetam, valproate or phenobarbital on febrile convulsions in rats[J]. CJCP, 2010, 12(07): 573-575.
［7］Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain ［J］. Br J Pharmacol, 2001, 133(6):867-874.
［8］Brockm-ller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levitiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A.B and C): characterization by dynamic liver function tests ［J］. Clin Pharmacol Ther, 2005, 77(6):529-541.
［9］Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levitiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents ［J］. Seizure, 2001, 10(4):279-286.
［10］Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? ［J］. Epilepsia, 2001, 42 (Suppl 4):13-18.
［11］Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam ［J］.Proc Natl Acad Sci USA, 2004, 101(26):9861-9866.
［12］Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal near ones of rat hippocampal slices ［J］. Neurosci Leet, 2001, 306 (1-2):5-8.
［13］Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture ［J］. Neurosci Lett, 2008, 436(3):289-293.
